The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). Detailed results will
The post Astellas, Pfizer’s XTANDI meets primary endpoint in phase 3 prostate cancer trial appeared first on Pharmaceutical Business review.